DK1889629T3 - Stabil formulering omfattende en kombination af et fugtsensitivt stof og et andet stof og fremgangsmåde til fremstilling deraf - Google Patents

Stabil formulering omfattende en kombination af et fugtsensitivt stof og et andet stof og fremgangsmåde til fremstilling deraf

Info

Publication number
DK1889629T3
DK1889629T3 DK06253596T DK06253596T DK1889629T3 DK 1889629 T3 DK1889629 T3 DK 1889629T3 DK 06253596 T DK06253596 T DK 06253596T DK 06253596 T DK06253596 T DK 06253596T DK 1889629 T3 DK1889629 T3 DK 1889629T3
Authority
DK
Denmark
Prior art keywords
substance
combination
moisture sensitive
preparation
stable formulation
Prior art date
Application number
DK06253596T
Other languages
English (en)
Inventor
Michael Fox
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1889629T3 publication Critical patent/DK1889629T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06253596T 2006-07-10 2006-07-10 Stabil formulering omfattende en kombination af et fugtsensitivt stof og et andet stof og fremgangsmåde til fremstilling deraf DK1889629T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06253596A EP1889629B1 (en) 2006-07-10 2006-07-10 Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof

Publications (1)

Publication Number Publication Date
DK1889629T3 true DK1889629T3 (da) 2008-12-15

Family

ID=37074674

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06253596T DK1889629T3 (da) 2006-07-10 2006-07-10 Stabil formulering omfattende en kombination af et fugtsensitivt stof og et andet stof og fremgangsmåde til fremstilling deraf

Country Status (6)

Country Link
EP (1) EP1889629B1 (da)
AT (1) ATE406173T1 (da)
DE (1) DE602006002514D1 (da)
DK (1) DK1889629T3 (da)
ES (1) ES2313578T3 (da)
PT (1) PT1889629E (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI23149A (sl) 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
US20050202083A1 (en) * 2002-08-02 2005-09-15 Kumar Pananchukunnath M Storage stable tablets of fosinopril sodium

Also Published As

Publication number Publication date
PT1889629E (pt) 2008-10-20
DE602006002514D1 (de) 2008-10-09
ATE406173T1 (de) 2008-09-15
EP1889629A1 (en) 2008-02-20
EP1889629B1 (en) 2008-08-27
ES2313578T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NO20064584L (no) Tetrahydropyridoindolderivater
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
NO20073601L (no) Immunresponsmodifikator-skumformuleringer
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
NO20076448L (no) Novel piperidine carboxylic acid amide derivatives
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
CL2009001183A1 (es) Formulación farmacéutica sólida que comprende a) cilostazol, b) 10 a 90% de un almidón pregelatinizado c) uno o más tipos de ingredientes entéricos, y d) un ácido orgánico.
DK1810676T3 (da) Levetiracetam formuleringer og fremgangsmåder til deres fremstilling
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
EA201100753A1 (ru) Композиции с пролонгированным высвобождением, содержащие производное 2-оксо-1-пирролидина
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren
NO20085423L (no) stabil formulering omfattende fuktighetsfolsomt legemiddel og fremgangsmate for fremstilling derav
DK1889629T3 (da) Stabil formulering omfattende en kombination af et fugtsensitivt stof og et andet stof og fremgangsmåde til fremstilling deraf
EA200801634A1 (ru) Твердая фармацевтическая композиция, содержащая ирбесартан
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner
WO2006021401A3 (en) Bicylononene derivatives
DK1818048T3 (da) Farmaceutiske formuleringer af alifatiske aminpolymerer og metoder til deres fremstilling
TW200621774A (en) Bicyclononene derivatives